Article Text

Download PDFPDF
CASE REPORT
Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab
  1. Luís Isidoro1,
  2. Paula Pires2,
  3. Luís Rito3,
  4. Gustavo Cordeiro1
  1. 1Department of Neurology, Coimbra Hospital and University Centre, Coimbra, Portugal
  2. 2Department of Neurology, Hospital de Santo Espírito, Angra do Heroísmo, Azores, Portugal
  3. 3Department of Haematology, Coimbra Hospital and University Centre, Coimbra, Portugal
  1. Correspondence to Dr Luís Isidoro, luis_isidoro{at}yahoo.com

Summary

A 69-year-old Caucasian woman with a 15-year history of refractory chronic lymphocytic B-cell leukaemia (CLL), treated with alemtuzumab in the past 10 months presented with a subacute right foot drop. Initial evaluation with a brain CT scan, lumbosacral MRI, nerve conduction studies and LP was negative. In the following months, progressive right hemibody weakness and dysarthria developed. Brain MRI showed a bilateral parasagittal frontal lesion. Alemtuzumab treatment was withdrawn. Progressive multifocal leukoencephalopathy (PML) was confirmed by PCR. Attempted antiviral therapies proved fruitless. Inexorable clinical deterioration ensued and the patient passed away 10 months after the presentation. This case report intends to call attention for PML as a potential fatal complication of severe immunosuppression, including the possible role of new monoclonal antibodies (such as alemtuzumab) in its pathogenesis.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.